Zhitong Finance App News, Chenxin Pharmaceutical (603367.SH) issued an announcement. Recently, the company's subsidiary Shandong Chenxin Fodu Pharmaceutical Co., Ltd. (“Fodu Pharmaceutical”) received the “Drug Registration Certificate” for clotiprednisolone eye drops approved and issued by the State Drug Administration.

Clotiprednisolone eye drops are classified as a chemical class 4. They are mainly used to treat eye inflammation that responds to steroids and associated or potential bacterial infections on the eye surface. Fodu Pharmaceutical's first application for registration of clotiprednisolone eye drops was accepted in 2025. This is the first time it has been marketed in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.